# A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

> **NCT06299124** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Regor Pharmaceuticals Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** RGT-419B

## Key facts

- **NCT ID:** NCT06299124
- **Lead sponsor:** Regor Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-17
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299124, "A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06299124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*